ClinicalTrials.gov
ClinicalTrials.gov Menu

A STUDY TO EVALUATE THE EFFICACY OF CJH1 (CLR4001) IN PARKINSON'S DISEASE

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01684475
Recruitment Status : Unknown
Verified September 2012 by Craig Hudson MD, Alexandra Marine and General Hospital.
Recruitment status was:  Recruiting
First Posted : September 13, 2012
Last Update Posted : September 13, 2012
Sponsor:
Information provided by (Responsible Party):
Craig Hudson MD, Alexandra Marine and General Hospital

Brief Summary:
The purpose of this study is to assess the ability of CJH1 to increase the sensitivity of dopamine receptors and thereby reduce symptoms of Parkinson's Disease.

Condition or disease Intervention/treatment Phase
Parkinson's Disease Drug: CJH1 (CLR4001) Phase 1 Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 21 participants
Intervention Model: Single Group Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A STUDY TO EVALUATE THE EFFICACY OF CJH1 [CLR4001] IN THE TREATMENT OF PARKINSON'S DISEASE
Study Start Date : September 2012
Primary Completion Date : September 2013
Estimated Study Completion Date : September 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Treatment with CJH1 Drug: CJH1 (CLR4001)



Primary Outcome Measures :
  1. Reduced signs and symptoms of Parkinson's disease [ Time Frame: 8 weeks ]
    Reduced signs and symptoms of Parkinson's disease



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient's with Parkinson's disease

Exclusion Criteria:

  • Contraindications to study medication

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01684475


Locations
Canada, Ontario
Gateway Rural Health Research Recruiting
Goderich, Ontario, Canada, N7A 1W5
Contact: Craig Hudson, MD    519-524-8323      
Principal Investigator: Craig J Hudson, MD         
Sponsors and Collaborators
Alexandra Marine and General Hospital

Responsible Party: Craig Hudson MD, Psychiatrist, Alexandra Marine and General Hospital
ClinicalTrials.gov Identifier: NCT01684475     History of Changes
Other Study ID Numbers: CJH1 Trial
First Posted: September 13, 2012    Key Record Dates
Last Update Posted: September 13, 2012
Last Verified: September 2012

Keywords provided by Craig Hudson MD, Alexandra Marine and General Hospital:
Novel Treatment Parkinson's disease

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases